LanzaTech Global, Inc.
LNZA Nasdaq Industrial Organic Chemicals Financials FY2022βFY2025
What LanzaTech Global, Inc. does
No business description yet.
- Legal name
- LanzaTech Global, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 31, 2026
- Accession Β· CIK
- 0001628280-26-022505
0001843724
Revenue and margins
LanzaTech Global, Inc. had $55.8M of revenue in fiscal 2025, up 12.6% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$66.1M in fiscal 2025, β118.4% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
LanzaTech Global, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 11.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably LanzaTech Global, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $83.0M | $75.6M | $43.5M | $13.2M |
| Debt incl. finance leases | $50.0M | $25.2M | β | β |
| Debt / equity | β | 0.2x | β | β |
| Current ratio | 2.2x | 6.2x | 3.3x | 1.4x |
| Quick ratio | 2.2x | 6.2x | 3.2x | 1.4x |
| Total assets | $177M | $242M | $175M | $100M |
| Total liabilities | $125M | $127M | $161M | $90.9M |
| Shareholders' equity | β$429M | $114M | $13.4M | β$3.9M |
| Net debt (β = net cash) | β$33.0M | β$50.4M | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 3 / 7 | 2 / 7 |
| Accruals ratio | 4.7% | β17.6% | β23.4% | 11.6% |
| Altman Z'' | β12.37 | β9.30 | β19.61 | β37.71 |
4 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $37.3M | $62.6M | $49.6M | $55.8M |
| Research and development | $53.2M | $68.1M | $77.0M | $53.2M |
| Operating income | β$75.6M | β$106M | β$109M | β$79.2M |
| Pretax income | β$1.0M | β$131M | β$123M | β$44.7M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$76.4M | β$134M | β$138M | β$49.0M |
| Net income to common | β$115M | β$138M | β$138M | β |
| Diluted EPS | β$12.37 | β$0.79 | β$69.71 | β$22.27 |
| Diluted shares | 0.01B | 0.18B | 0.00B | 0.00B |
| Cash flow | ||||
| Cash from operations | β$84.7M | β$97.3M | β$89.1M | β$64.9M |
| Capital expenditure | $10.7M | $8.6M | $5.3M | $1.3M |
| Free cash flow | β$95.4M | β$106M | β$94.4M | β$66.1M |
| Depreciation and amortization | $4.7M | $5.5M | $5.6M | $4.2M |
| Stock-based compensation | $2.5M | $15.2M | $13.2M | $7.2M |
| Balance sheet | ||||
| Cash and short-term investments | $83.0M | $75.6M | $43.5M | $13.2M |
| Total debt | $50.0M | $25.2M | β | β |
| Current assets | $124M | $173M | $99.3M | $39.7M |
| Current liabilities | $56.0M | $27.8M | $30.4M | $27.7M |
| Inventory | $1.1M | $1.8M | $2.2M | $0.7M |
| Property and equipment, net | $19.7M | $22.8M | $22.3M | $17.1M |
| Total assets | $177M | $242M | $175M | $100M |
| Total liabilities | $125M | $127M | $161M | $90.9M |
| Preferred stock | $0.0M | β | β | β |
| Shareholders' equity | β$429M | $114M | $13.4M | β$3.9M |
| Margins | ||||
| Operating margin | β202.4% | β169.9% | β219.7% | β141.7% |
| EBITDA margin | β190.0% | β161.1% | β208.4% | β134.2% |
| Net margin | β204.5% | β214.1% | β277.7% | β87.7% |
| FCF margin | β255.6% | β169.0% | β190.3% | β118.4% |
| Returns | ||||
| Return on capital | β | β131.2% | β | β |
| Return on capital employed | β62.5% | β49.7% | β75.5% | β109.2% |
| Return on equity | β | β | β215.3% | β1,024.6% |
| Return on assets | β43.2% | β64.1% | β66.2% | β35.6% |
| Return on tangible equity | β | β120.7% | β1,024.3% | β |
| Growth | ||||
| Revenue growth | β | 67.7% | β20.8% | 12.6% |
| Share count change | β | 1,792.3% | β98.9% | 11.2% |
| Financial health | ||||
| Debt / equity | β | 0.2x | β | β |
| Current ratio | 2.2x | 6.2x | 3.3x | 1.4x |
| Quick ratio | 2.2x | 6.2x | 3.2x | 1.4x |
| Capital allocation | ||||
| Capex / revenue | 28.7% | 13.7% | 10.7% | 2.3% |
| Stock comp / revenue | 6.8% | 24.3% | 26.6% | 12.9% |
| Quality scores | ||||
| Piotroski F-score | β | 4.0 | 3.0 | 2.0 |
| Altman Z'' | β12.4 | β9.3 | β19.6 | β37.7 |
| Accruals ratio | 4.7% | β17.6% | β23.4% | 11.6% |
Source: SEC EDGAR XBRL filings (CIK 0001843724). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.